162 companies with bright spots in pharmaceutical industry segment net profit growth

Source: China Securities Journal, August 31, 2017, medical network, Caihui financial big data statistics show that the 2017 half year report of 262 pharmaceutical companies shows that the net profit of 162 companies has increased, 90 companies have declined and 10 companies have lost money On the whole, the operation of pharmaceutical companies is stable and the overall performance is relatively flat Under the influence of stricter environmental protection supervision, the capacity of API contracted, stimulating the price rise In addition, there are highlights in the segmentation fields of pharmaceutical retail, pharmaceutical consumer goods and medical services Industry insiders said that since the implementation of the "new medical reform", the efforts to control medical insurance fees have increased year by year, and the pressure has been transmitted to pharmaceutical enterprises With the implementation of supporting policies for medical reform in the second half of the year, drug bidding and procurement will be carried out intensively, and the industry will continue to bear pressure According to the net profit growth data of 162 companies, the total operating revenue of 262 pharmaceutical companies increased by about 6% and the net profit increased by about 8% Among 162 companies with net profit growth, 19 companies including Zhifei biology, Northeast Pharmaceutical, Tiantan biology, Zixin pharmaceutical, Sihuan biology, Huayuan biology, Zhendong pharmaceutical, etc increased by more than 100% The expansion of sales scale, the listing of new products and the consolidation of external expansion have become the main reasons for the growth of performance Due to the strict environmental protection, many API enterprises were stopped production and limited production, which stimulated the price rise of API As a result, the net profit of Northeast Pharmaceutical and garden biology increased significantly Qiu min, a pharmaceutical researcher at Huachuang securities, believes that due to the stricter environmental supervision, the capacity of API will be further compressed and the price increase of API is expected to continue The net profit of 18 companies increased by 30% - 100%, including Haiwang bio, Yong'an pharmaceutical, Peking University pharmaceutical, Jiuzhou pharmaceutical, Watson bio, Changsheng bio, etc The growth was mainly due to the consolidation of acquired assets and the scale of sales In addition, 125 companies grew by less than 30% The net profit of 50 companies declined, including Jiaying pharmaceutical, Shuanglu pharmaceutical, Jianmin group, dongfelong, hiprec, Saito biology, Xiangxue pharmaceutical, and Changbu pharmaceutical Among them, step pharmaceutical was launched in November 2016 The pharmaceutical industry is facing challenges in the first half of this year The growth rate of revenue in the pharmaceutical manufacturing industry is 10%, returning to the double-digit level, which has recovered from the same period last year Yu Mingde, President of China Pharmaceutical Enterprise Management Association, told China Securities News that in the first half of 2015, the revenue growth rate of pharmaceutical manufacturing industry reached a new low in recent 15 years, with a growth rate of only 8.76% The growth rate of industry income fell below 10%, only before 2000 At that time, the situation was due to the lack of medical insurance system for urban employees In 2003 and 2007, the new rural cooperative medical system (NRCMS) and the urban residents' medical insurance system were established respectively With the continuous release of aging demand, it is rare for the growth rate to fall below double digits It is understood that with the increasing efforts of medical insurance and fee control year by year, the pharmaceutical industry is facing great challenges, the proportion of hospital drugs is becoming smaller and smaller, the strengthening of drug flight inspection, drug bidding and price reduction, and the increasing restrictions on auxiliary drugs, antibiotics, large infusion, etc., have a significant impact on the pharmaceutical industry.